STOCK TITAN
  1. Home
  2. Sec-filings
  3. PTCT
  4. [144] PTC THERAPEUTICS, INC. SEC Filing

PTCT Therapeutics (PTCT) insider to sell 10,292 vested shares under Rule 144

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Matthew Klein has filed to sell common stock of PTCT under Rule 144. The filing covers 10,292 shares of common stock to be sold through Fidelity Brokerage Services LLC on or after August 4, 2026 on NASDAQ, with an aggregate market value of $705,754.35. These shares arose from restricted stock vesting granted by the issuer as compensation on August 3, 2026. The filing also reports that on May 14, 2026, Klein previously sold 12,572 shares of common stock for an aggregate market value of $917,129.43.

Positive

  • None.

Negative

  • None.
Shares proposed for sale 10,292 shares Common stock to be sold through Fidelity Brokerage Services LLC
Aggregate market value (proposed sale) $705,754.35 Market value of 10,292 common shares to be sold on NASDAQ
Planned sale date 08/04/2026 Date on or after which the 10,292 shares may be sold
Restricted stock vesting date 08/03/2026 Date the 10,292 compensation shares vested
Prior shares sold 12,572 shares Common stock sold on 05/14/2026 during past three months
Aggregate market value (prior sale) $917,129.43 Market value of 12,572 shares sold on 05/14/2026
Rule 144 regulatory
"has filed to sell common stock of PTCT under Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
restricted stock vesting financial
"These shares arose from restricted stock vesting granted by the issuer"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
aggregate market value financial
"with an aggregate market value of $705,754.35"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
compensation financial
"granted by the issuer as compensation on August 3, 2026"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FAQ

What does the PTCT Form 144 filing by Matthew Klein disclose?
The filing discloses that Matthew Klein plans to sell 10,292 PTCT common shares under Rule 144. These shares came from restricted stock vesting granted as compensation and are to be sold through Fidelity Brokerage Services LLC on NASDAQ.

How many PTCT shares are proposed to be sold in this Form 144?
The Form 144 covers a proposed sale of 10,292 PTCT common shares. The filing states an aggregate market value of $705,754.35 for these shares, with sales expected to occur on or after August 4, 2026 on NASDAQ.

What is the origin of the PTCT shares in Matthew Klein’s planned sale?
The 10,292 PTCT shares were acquired through restricted stock vesting. The vesting occurred on August 3, 2026 and is identified in the filing as stock granted by the issuer as compensation before the planned Rule 144 sale.

What prior PTCT stock sales by Matthew Klein are reported in this Form 144?
The filing reports that on May 14, 2026, Matthew Klein sold 12,572 PTCT common shares. The transaction had an aggregate market value of $917,129.43, and it is listed under securities sold during the past three months.

Which broker and market are involved in the planned PTCT share sale?
The planned sale of 10,292 PTCT common shares will be executed through Fidelity Brokerage Services LLC. The filing specifies that the shares are to be sold on the NASDAQ market beginning on or after August 4, 2026.

What is the aggregate market value of the PTCT shares in the new proposed sale?
For the proposed sale of 10,292 PTCT shares, the filing lists an aggregate market value of $705,754.35. This figure reflects the market value used for the Rule 144 notice related to the planned NASDAQ transactions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR